K. Gorski

发表

Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1

Lieping Chen, D. Pardoll, K. Tamada, 2002, The Journal of Immunology.

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

A. Ohtsu, H. Murakami, T. Yoshino, 2011, Cancer Chemotherapy and Pharmacology.

First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer

C. Yunis, Jeffrey S. Miller, A. Dudek, 2007, Clinical Cancer Research.

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.

L. Boulet, P. O'Byrne, D. Cockcroft, 2014, The New England journal of medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor

Lieping Chen, D. Pardoll, J. Powell, 2003, The Journal of experimental medicine.

Evidence for Four Distinct Major Protein Components in the Paraflagellar Rod of Trypanosoma cruzi *

Mark J. Miller, M. Miller, J. Manning, 1998, The Journal of Biological Chemistry.

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer.

Loise M. Francisco, D. Pardoll, E. Kelleher, 2003, Molecular immunology.

Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells

D. Pardoll, Yan Cui, C. Civin, 2003, Nature Medicine.

Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

M. Ross, R. Dummer, L. Demidov, 2019, Annals of Oncology.

Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8

M. Tomai, R. Kedl, J. Vasilakos, 2005, The Journal of Immunology.

CCR4 improves phenotypic identification of T-regulatory cells; Validation and implementation of clinical test

C. Cox, M. Gavin, J. Ferbas, 2010 .

TLR8 Differences between Human TLR7 and Synthetic TLR Agonists Reveal Functional

M. Tomai, R. Kedl, J. Vasilakos, 2005 .

Homeostasis of Human NK Cells Is Not IL-15 Dependent

M. Retter, H. Lebrec, M. Horner, 2013, The Journal of Immunology.

DependentHomeostasis of Human NK Cells Is Not IL-15

M. Retter, H. Lebrec, K. Narayanan, 2013 .

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2014 .

Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.

D. Pardoll, C. Civin, Linzhao Cheng, 2002, Blood.

Abstract C6: Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor‐5 agonist antibody, in Japanese patients with advanced solid tumors

A. Ohtsu, H. Murakami, N. Yamamoto, 2009 .

Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8

M. Tomai, R. Kedl, J. Vasilakos, 2005, Journal of Immunology.

CD137 Receptor by Dendritic Cells Cutting Edge: Expression of Functional

Lieping Chen, D. Pardoll, K. Tamada, 2002 .

B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

D. Pardoll, S. Pai, T. Shin, 2001, The Journal of experimental medicine.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A. Tolcher, I. Puzanov, K. Papadopoulos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous Stem Cell Treatments for High Risk Neuroblastoma

K. Gorski, Gallicchio Vs, 2018 .

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Jeffrey S. Miller, M. Tomai, J. Vasilakos, 2006, International immunology.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

M. Ross, L. Demidov, A. Berger, 2021, Nature Medicine.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

An Immunodominant MHC Class II-Restricted Tumor Antigen Is Conformation Dependent and Binds to the Endoplasmic Reticulum Chaperone, Calreticulin1

T. Elliott, D. Pardoll, M. Edidin, 2001, The Journal of Immunology.

Conformation Dependent and Binds to the II-Restricted Tumor Antigen Is An Immunodominant MHC Class

E. Jaffee, D. Pardoll, M. Edidin, 2001 .

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

C. Dumitru, M. Tomai, Sean M. Mcgurran, 2009, Cancer Immunology, Immunotherapy.

Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells

T. Yuraszeck, K. Park, S. Sohn, 2017 .

Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR.

D. Pardoll, Q. Jiang, Tianhong Wang, 2009, Blood.

Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Michael E. Lassman, J. Malvehy, R. Dummer, 2018 .

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

D. Schadendorf, J. Malvehy, H. Gogas, 2021, Journal for ImmunoTherapy of Cancer.

Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study.

D. Schadendorf, J. Malvehy, R. Gutzmer, 2018, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .